Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Cytisine Symposium at the Annual Society for Research in Nicotine and Tobacco Conference "SRNT"
By a News Reporter-Staff News Editor at Pharma Business Week Achieve Life Sciences, Inc. ("Achieve"), and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) ("OncoGenex") announced that the Society for Research in Nicotine and Tobacco (SRNT) will be holding a symposium on cytisine research at this year's annual conference, to be held at the Firenze Fiera Congress and Exhibition Center in Florence, Italy from March 7th - 11th. The cytisine symposium will be on Friday 10th March at 10:30 a.m (see also Pharmaceutical Companies).
Professor Nancy Rigotti, MD, Massachusetts General Hospital/Harvard Medical School is chairing the symposium, with presentations from Associate Professor Natalie Walker, PhD, National Institute for Health Innovation, University of Auckland, on "Cytisine versus Varenicline for Smoking Cessation: Two Clinical Trials from the Australasian Cytisine Trialist Group" and "The Challenge to Getting Cytisine Licensed For Use Worldwide: Policy Considerations". Dr. Walker conducted the 2014 CASCAID Phase 3 clinical trial - a 1,310 patient trial comparing cytisine to nicotine replacement therapy.
Further to Achieve's collaboration with the National Institute of Health (NIH) to advance research on cytisine, Dr. David Shurtleff, PhD and Deputy Director at the NIH, National Center for Complementary and Integrative Health, will also be presenting: "The Regulatory Science of Cytisine: Results from Pre-Clinical GLP-Regulated Safety Assessment".
Other topics to be covered at the symposium include a presentation on cytisine for smoking cessation in tuberculosis patients, to be presented by Kamran Siddiqi, PhD, University of York; and a presentation by SooHee Jeong, PhD, University of Auckland, about the concentration-effect relationship in smokers in relation to plasma cytisine concentrations, cigarette craving, withdrawal, smoking satisfaction and mood.
Dr. Anthony Clarke, PhD, Chief Scientific Officer of Achieve commented, "Significant research advances are progressing with cytisine. Achieve appreciates the contributions from the scientific community in aiding Achieve in its efforts to obtain regulatory approval for cytisine as a cost-effective smoking cessation treatment".
Professor Nancy Rigotti added, "The scientific community considers cytisine to potentially be a globally affordable tobacco cessation treatment. Regulatory authorities should be encouraged to progress the availability of cytisine as a matter of priority."
Two Phase 3 clinical trials of cytisine have been successfully completed in over 2,000 patients. The TASC Phase 3 trial was a 740 patient, double-blind placebo controlled trial conducted by University College London. The CASCAID trial was a 1,310 patient, single-blind trial comparing cytisine to nicotine replacement therapy. Both trials were published in the New England Journal of Medicine in December 2011 and December 2014 respectively.
Achieve announced on 5th January that it has entered into a definitive merger agreement with OncoGenex Pharmaceuticals, Inc.
Keywords for this news article include: OncoGenex Pharmaceuticals Inc., Smoking, Clinical Research, Biopharmaceutical Companies, Clinical Trials and Studies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC